Page last updated: 2024-09-02

ecteinascidin 743 and Meningioma

ecteinascidin 743 has been researched along with Meningioma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Balaná, C; Bendszus, M; Bonneville-Levard, A; Brandal, P; Brazil, L; Bromberg, J; Bronnimann, C; Bruna, J; Cameron, A; Clement, PM; Coens, C; Ducray, F; Dumont, S; Erridge, S; Furtner, J; Golfinopoulos, V; Gorlia, T; Le Rhun, E; Lefranc, F; Lewis, J; Lombardi, G; Lorgis, V; Mair, MJ; Marosi, C; Mawrin, C; Pichler, J; Preusser, M; Reijneveld, JC; Sahm, F; Sanson, M; Sepulveda, JM; Sievers, P; Silvani, A; Soffietti, R; Thon, N; Vauleon, E; Weller, M; Wick, W1
Alvarez-Breckenridge, CA; Brastianos, PK; Cahill, DP1
Berger, W; Dieckmann, K; Lötsch, D; Marosi, C; Preusser, M; Saringer, W; Schmook, M; Spiegl-Kreinecker, S; Wöhrer, A1

Trials

1 trial(s) available for ecteinascidin 743 and Meningioma

ArticleYear
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
    Neuro-oncology, 2022, 05-04, Volume: 24, Issue:5

    Topics: Adult; Brain Neoplasms; Disease-Free Survival; Humans; Meningeal Neoplasms; Meningioma; Quality of Life; Trabectedin; World Health Organization

2022

Other Studies

2 other study(ies) available for ecteinascidin 743 and Meningioma

ArticleYear
Trabectedin for recurrent WHO grade 2 or 3 meningiomas-Paving the road for new opportunities.
    Neuro-oncology, 2022, 05-04, Volume: 24, Issue:5

    Topics: Brain Neoplasms; Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Trabectedin; World Health Organization

2022
Trabectedin has promising antineoplastic activity in high-grade meningioma.
    Cancer, 2012, Oct-15, Volume: 118, Issue:20

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dioxoles; Drug Evaluation, Preclinical; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured

2012